Cover Image
市場調查報告書

惡病質:開發中產品分析

Cachexia - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 192512
出版日期 內容資訊 英文 158 Pages
訂單完成後即時交付
價格
Back to Top
惡病質:開發中產品分析 Cachexia - Pipeline Review, H2 2015
出版日期: 2015年09月30日 內容資訊: 英文 158 Pages
簡介

惡病質常見於包含第一型糖尿病的慢性疾病,多發性硬化症,HIV,癌症,及隨著高齡化的「發育障礙」症候群患者,會豦烈體重減輕及肌肉萎縮。症狀有無法控制地體重減輕、肌肉骨骼的消耗、食欲不振、QOL(生活品質)低落等。治療方法有使用飲食療法、營養補充品、運動及投藥療法等。

本報告網羅全球惡病質治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,再加上主要企業及開發中的產品檢討等。

目錄

簡介

  • 分析範圍

惡病質概要

治療藥的開發

  • 惡病質開發中產品:概要
  • 惡病質開發中產品:比較分析

惡病質:開發中的治療藥 - 各企業

惡病質:開發中的治療藥 - 大學·研究機關別

惡病質:開發中產品概況

  • 臨床實驗階段的產品
  • 初期階段的產品

惡病質:開發中的產品 - 各企業

惡病質:開發中的產品 - 大學·研究機關別

惡病質:治療藥的開發企業

  • GlaxoSmithKline plc
  • Plexxikon Inc.
  • BioLineRx, Ltd.
  • Novartis AG
  • Aphios Corporation
  • Calzada Limited.
  • Palatin Technologies, Inc.
  • Cytokinetics, Incorporated
  • Fate Therapeutics, Inc.
  • AVEO Pharmaceuticals, Inc.
  • Fountain Biopharma Inc.
  • Rhythm Pharmaceuticals.
  • MI.TO. Technology S.r.L.

惡病質:治療藥的評估

  • 單劑治療藥
  • 標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 產品概要
  • 作用機制
  • R&D的進展

最新的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6965IDB

Summary

Global Markets Direct's, 'Cachexia - Pipeline Review, H2 2015', provides an overview of the Cachexia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cachexia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cachexia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cachexia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cachexia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cachexia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cachexia Overview
  • Therapeutics Development
    • Pipeline Products for Cachexia - Overview
    • Pipeline Products for Cachexia - Comparative Analysis
  • Cachexia - Therapeutics under Development by Companies
  • Cachexia - Therapeutics under Investigation by Universities/Institutes
  • Cachexia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Cachexia - Products under Development by Companies
  • Cachexia - Products under Investigation by Universities/Institutes
  • Cachexia - Companies Involved in Therapeutics Development
    • Acacia Pharma Limited
    • Aeterna Zentaris Inc.
    • Amgen Inc.
    • Aphios Corporation
    • Atara Biotherapeutics, Inc.
    • Connexios Life Sciences Pvt. Ltd.
    • Eli Lilly and Company
    • GlaxoSmithKline Plc
    • GTx, Inc.
    • Helsinn Healthcare S.A.
    • Incyte Corporation
    • KAEL-GemVax Co., Ltd.
    • MI.TO. Technology S.r.L.
    • Myos Corporation
    • Novartis AG
    • Obexia AG
    • PolyNovo Limited
    • PsiOxus Therapeutics Limited
    • Radius Health, Inc.
    • RaQualia Pharma Inc.
    • Rhythm Pharmaceuticals
    • VBS Pharmaceuticals
    • Vicus Therapeutics, LLC
    • Viking Therapeutics, Inc.
  • Cachexia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (etodolac + propranolol hydrochloride) - Drug Profile
    • (formoterol fumarate + megestrol acetate) - Drug Profile
    • anamorelin hydrochloride - Drug Profile
    • Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile
    • AOD-9604 - Drug Profile
    • Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile
    • ARM-210 - Drug Profile
    • ATA-842 - Drug Profile
    • AV-380 - Drug Profile
    • bimagrumab - Drug Profile
    • C-1889 - Drug Profile
    • CAR Peptide - Drug Profile
    • CNX-013B2 - Drug Profile
    • DLN-101 - Drug Profile
    • dronabinol - Drug Profile
    • Drug to Antagonize ActRIIB for Cancer Cachexia - Drug Profile
    • enobosarm - Drug Profile
    • Espindolol - Drug Profile
    • EXT-400 - Drug Profile
    • GSK-2881078 - Drug Profile
    • landogrozumab - Drug Profile
    • macimorelin acetate - Drug Profile
    • Monoclonal Antibody to Antagonize TWEAK Receptor for Cachexia and Cancer Cachexia - Drug Profile
    • NBD Peptide - Drug Profile
    • OBX-1201 - Drug Profile
    • Proteins for Musculoskeletal Disorders - Drug Profile
    • RAD-140 - Drug Profile
    • relamorelin - Drug Profile
    • RQ-00432933 - Drug Profile
    • ruxolitinib phosphate - Drug Profile
    • Small Molecule to Agonize Ghrelin Receptor for Cancer Cachexia and Anorexia - Drug Profile
    • Small Molecule to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile
    • Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile
    • Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile
    • Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure - Drug Profile
    • Small Molecules to Target Melanocortin-4 Receptor for Cachexia - Drug Profile
    • Synthetic Peptide to Inhibit Melanocortin Receptor for Cancer Cachexia - Drug Profile
    • Synthetic Peptides for Cancer Cachexia - Drug Profile
    • tertomotide - Drug Profile
    • VK-5211 - Drug Profile
  • Cachexia - Recent Pipeline Updates
  • Cachexia - Dormant Projects
  • Cachexia - Discontinued Products
  • Cachexia - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cachexia, H2 2015
  • Number of Products under Development for Cachexia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Cachexia - Pipeline by Acacia Pharma Limited, H2 2015
  • Cachexia - Pipeline by Aeterna Zentaris Inc., H2 2015
  • Cachexia - Pipeline by Amgen Inc., H2 2015
  • Cachexia - Pipeline by Aphios Corporation, H2 2015
  • Cachexia - Pipeline by Atara Biotherapeutics, Inc., H2 2015
  • Cachexia - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2015
  • Cachexia - Pipeline by Eli Lilly and Company, H2 2015
  • Cachexia - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Cachexia - Pipeline by GTx, Inc., H2 2015
  • Cachexia - Pipeline by Helsinn Healthcare S.A., H2 2015
  • Cachexia - Pipeline by Incyte Corporation, H2 2015
  • Cachexia - Pipeline by KAEL-GemVax Co., Ltd., H2 2015
  • Cachexia - Pipeline by MI.TO. Technology S.r.L., H2 2015
  • Cachexia - Pipeline by Myos Corporation, H2 2015
  • Cachexia - Pipeline by Novartis AG, H2 2015
  • Cachexia - Pipeline by Obexia AG, H2 2015
  • Cachexia - Pipeline by PolyNovo Limited, H2 2015
  • Cachexia - Pipeline by PsiOxus Therapeutics Limited, H2 2015
  • Cachexia - Pipeline by Radius Health, Inc., H2 2015
  • Cachexia - Pipeline by RaQualia Pharma Inc., H2 2015
  • Cachexia - Pipeline by Rhythm Pharmaceuticals, H2 2015
  • Cachexia - Pipeline by VBS Pharmaceuticals, H2 2015
  • Cachexia - Pipeline by Vicus Therapeutics, LLC, H2 2015
  • Cachexia - Pipeline by Viking Therapeutics, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Cachexia Therapeutics - Recent Pipeline Updates, H2 2015
  • Cachexia - Dormant Projects, H2 2015
  • Cachexia - Dormant Projects (Contd..1), H2 2015
  • Cachexia - Dormant Projects (Contd..2), H2 2015
  • Cachexia - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Cachexia, H2 2015
  • Number of Products under Development for Cachexia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top